Mason Hayes & Curran Advises J.P. Morgan Securities plc on Alkermes’ Proposed Acquisition of Avadel Pharmaceuticals

"Mason Hayes & Curran advised J.P. Morgan Securities plc, acting as financial adviser to Alkermes, on Alkermes' proposed acquisition of Avadel Pharmaceuticals plc valued at up to $2.37 billion. The transaction is to be implemented by a recommended scheme of arrangement under Irish law and is subject to shareholder and regulatory approvals."

Mason Hayes & Curran advised J.P. Morgan Securities plc, acting as financial adviser to Alkermes, in connection with Alkermes plc's proposed acquisition of Avadel Pharmaceuticals plc. The proposed transaction, valued at up to $2.37 billion, concerns Avadel, an Irish‑incorporated, Nasdaq‑listed biopharmaceutical company best known for Lumryz, its FDA‑approved treatment for narcolepsy. Alkermes, also Nasdaq‑listed and headquartered in Ireland, is a global biopharmaceutical company. The acquisition is to be effected by way of a recommended scheme of arrangement under Irish law and remains subject to shareholder and regulatory approvals. Mason Hayes & Curran represented J.P. Morgan Securities plc, the financial adviser to Alkermes, with a team composed by: Partners Anne Harkin and Justin McKenna (Corporate); Associates Gareth Black and Dean Molyneaux; and Trainee India Kelly. The firm noted its recent track record advising on the majority of takeovers of Irish public companies, acting for bidders, targets and cash‑confirming financial advisers on comparable mandates.

Mason Hayes & Curran Advises J.P. Morgan Securities plc on Alkermes’ Proposed Acquisition of Avadel Pharmaceuticals

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads